"Revolutionizing Biotech: How mRNA Targeting is Changing the Game"

Biotech company Molecure is developing small molecule therapies that target mRNA to treat incurable diseases such as cancer and inflammatory diseases. Their RNA platform uses computational and experimental methods to identify and optimize hit compounds that selectively "lock" the mRNA of interest, preventing the expression of disease-related proteins. Molecure integrates bioinformatics methods to assess off-target effects and uses a target-based approach to yield hits specific to RNA. The company is also developing a machine learning approach to speed up the virtual screening process. Challenges include selecting suitable druggable regions and translating results from in vitro studies to living organisms. Molecure aims to deliver new drugs quickly through collaborations with pharmaceutical companies.